Skip to main content
Fig. 5 | Cancer & Metabolism

Fig. 5

From: Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

Fig. 5

TOFA treatment delays engraftment and splenic infiltration. A Luciferase-labeled MYC-driven lymphoma cells from Eμ-tTA/Tet-O-MYC-conditional transgenic murine model were intravenously injected into NSG mice and quantitated over time using bioluminescence imaging (BLI). Mice treated with TOFA show significantly decreased signal indicating reduced engraftment. B Further analysis of the spleens from the mice utilized in panel A revealed significantly reduced spleen size in TOFA-treated animals compared to vehicle control, suggesting decreased infiltration. C Eμ-tTA/Tet-O-MYC (primary model of T-ALL) mice were treated with TOFA at 5 weeks of age for 1 week and tracked for an additional 4 weeks. TOFA-treated mice were less moribund and exhibited significantly reduced spleen mass, suggesting inhibition of lipogenesis results in reduced disease onset and severity. D RAS and BCR-ABL driven T-ALL cell lines were allografted subcutaneously into NSG mice. We detected significantly reduced tumor volume for mice treated with TOFA. We also observed attenuated tumor volume using the human B cell lymphoma cell lines P493-6 subcutaneously xenografted on NSG mice. Comparisons to vehicle control utilized unpaired t-test. *P ⩽ 0.1; **P ⩽ 0.01

Back to article page